 Home > Active Pharmaceutical Ingredients > Inhibitor Drugs > Retatrutide for Sale > Retatrutide 2381089-83-2 API

Retatrutide 2381089-83-2 API buy - large image1

Retatrutide 2381089-83-2 API buy - image1

Retatrutide 2381089-83-2 API buy - image2

Retatrutide 2381089-83-2 API buy - image3

Retatrutide 2381089-83-2 API buy - image4

Retatrutide 2381089-83-2 API

Name: Retatrutide 2381089-83-2 API
Brand: orient
SKU: pr2605081825
Price: 33 USD
Availability: OutOfStock

7488 Inquiries

Unit Price: Get Latest Price 

CAS No.:

2381089-83-2

Grade:

Industrial Grade

Content:

99%

Port:

shanghai

Brand:

orient

Packaging:

1KG, 5KG, 25KG

Sample Available:

Yes

Price valid (until):

2026-06-08

 The product will be displayed normally on the website later.

Qingdao Orient Chemical Co.,LTD

Company Type:

Trader

Location:

China

Payment Terms:

100% TT in advance

Average Lead Time:

10 days

Qualification:

Main Products:

pharmaceutical intermediates,peptides,electronic chemicals

 Visit Store

Product Details
Seller Information
Inquiry History

Description

Retatrutide Basic information

Product Name:	Retatrutide
Synonyms:	LY3437943;Retatrutide;GIPR/GLP-1R;Retatrutide/LY3437943/GIPR/GLP-1R;Retaglutide;Retatrutide acetate;LY3437943Retatrutide;Retalutide
CAS:	2381089-83-2
MF:
MW:	0
EINECS:	200-001-8
Product Categories:
Mol File:	Mol File

Retatrutide Chemical Properties

storage temp.	-20°C
solubility	Acetonitrile: Slightly soluble DMSO: Sparingly Soluble: 1-10mg/mLPBS (pH 7.2): Sparingly Soluble: 1-10mg/mL Water: Slightly soluble
form	powder
color	White lyophilized
Water Solubility	Soluble in water (5mg/ml).

Safety Information

MSDS Information

Retatrutide Usage And Synthesis

Description	Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent otropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide inhibits human GCGR, GIPR and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively and mouse GCGR, GIPR, and GLP-1R with EC50 values of 2.32, 0.191 and 0.794 nM, respectively. It is an important tool for obesity research. Retatrutide potently activates the GLP-1R signaling pathway to stimulate glucose-dependent secretion through activity at the GIP receptor (GIPR) or the GLP-1R. Retatrutide is a synthetic peptide with glucose-lowering effects. It is an antidiabetic agent against type 2 diabetes (T2D), stimulating and suppressing glucagon secretion in a glucose-dependent manner. Retatrutide was also shown to delay gastric emptying, lower fasting and postprandial glucose concentration, decrease food intake and reduce body weight in patients with type 2 diabetes.
History	Retatrutide (LY-3437943) was discovered by the American pharmaceutical company Eli Lilly and Company. It is a triple glucagon hormone receptor agonist (GLP-1, GIP, and GCGR receptors) for obesity. The 2024 Lasker~DeBakey Clinical Medical Research Award has been given to Joel Habener and Svetlana Mojsov for their discovery of a new hormone GLP-1(7-37) and to Lotte Knudsen for her role in developing sustained acting versions of this hormone as a treatment for obesity.
Biological Activity	Retatrutide (LY3437943), a single peptide conjugated to a lipid diacid molecule, exerts a powerful agonist effect on the human glucagon‐receptor (GCGR), GIPR, and GLP‐1R. In comparison with the human glucagon and glucagon‐like peptide 1 (GLP‐1), retatrutide exhibits reduced potency (by a factor of 0.3 and 0.4, respectively) on the GCGR and GLP‐1R while displaying enhanced potency at the human GIPR (by a factor of 8.9) when compared to the glucose‐dependentotropic polypeptide (GIP)[7].
Mechanism of action	When incted into mice suffering from diabetes-induced kidney injury, retatrutide was found to markedly reduce albuminuria levels while also increasing renal filtration rate. This was attributed to its ability to activate GLP-1R/GR-dependent signalling pathways, which then produced anti-inflammatory and antiapoptotic effects that protected the kidneys from further damage. Additionally, it has been shown to directly modulate glomerular permeability, thus leading to improved urinary concentration. Initial results indicate that the peptide can induce marked improvements in albuminuria levels within just four weeks of treatment when compared to other treatments for chronic kidney disease such as ACE inhibitors or angiotensin receptor blockers (ARBs). Moreover, retatrutide has demonstrated a greater effect than either ACE inhibitors or ARBs at reducing systolic blood pressure without inducing significant side effects.
Side effects	The most common side effects of retatrutide are gastrointestinal, including: Nausea, Diarrhea, Vomiting, and Constipation. At higher doses, researchers stated these symptoms were "mostly mild to moderate in severity" and typically treated by lowering the dosage. However, 7% of patients also experienced skin tingling. At 24 weeks of treatment, patients' heart rates on higher doses peaked but declined afterward.
in vitro	In vitro, Retatrutide demonstrates similar efficacy to natural glucagon in evoking glucose production within hepatocytes. Meanwhile, in adipocytes, it surpasses native GIP in inducing lipolysis. Retatrutide is effective in reducing weight in individuals with nonsyndromic obesity. Retatrutide demonstrates dosage‐dependent pharmacokinetics, featuring a favourable half‐life of nearly 6 days, enabling convenient weekly administration. Additionally, GLP‐1 and GCG are known to significantly delay GE in humans, while GIP may have no impact on GE. Delayed GE reduces food consumption and, therefore, leads to weight reduction[7].
References	[1] LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept: T. Coskun, et al.; Cell Metab. 34, 1234 (2022) DOI:10.1016/j.cmet.2022.07.013 [2] The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying: S. Urva, et al.; Diabetes Obes. Metab. 25, 2784 (2023) DOI:10.1111/dom.15167 [3] LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial: S. Urva, et al.; Lancet 400, 1869 (2022) DOI:10.1016/S0140-6736(22)02033-5 [4] Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity S.A. Doggrell; Expert Opin. Investig. Drugs 32, 355 (2023) DOI:10.1080/13543784.2023.2206560 [5] Differentiation of human subcutaneous adipocytes and measurement of lipolytic function induced by GIP or LY3437943: A. Regmi & W. Roell; STAR Protoc. 4, 102304 (2023) DOI:10.1016/j.xpro.2023.102304 [6] Gut hormone co-agonists for the treatment of obesity: from bench to bedside: R. Nogueiras, et al.; Nature Metab. 5, 933 (2023) (Review) DOI:10.1038/s42255-023-00812-z [7] Muhammad Naeem, Umm E Salma Shabbar Banatwala, Laiba Imran. “Unleashing the power of retatrutide: A possible triumph over obesity and overweight: A correspondence.” Health Science Reports 7 2 (2024).

Shop Tirzepatide API Material-Detailed Image 3

Q1:Do you provide sample?

A: Yes, we can provide free sample, you only need pay the shipping cost.

Q2: What is the lead time?

A: For stock goods, it usually take about 5-7 days by air, 15-30 days by sea,For customized products, the delivery time needs to be confirmed based on the actual situation.

Q3: How can I buy? What is the payment method?

A: You can contract us through Email or you can browse our website:orientchem.cc, we have bank transfer,

Q4:What if there are quality issues？

A：We attach great importance to after-sales service of our products. If there are any quality issues, please contact us within 30 days of receiving the goods and we will handle returns and exchanges for you.

ECHEMI Editorial Reference

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide inhibits human GCGR, GIPR and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively and mouse GCGR, GIPR, and GLP-1R with EC50 values of 2.32, 0.191 and 0.794 nM, respectively. It is an important tool for obesity research.Retatrutide potently activates the GLP-1R signaling pathway to stimulate glucose-dependent insulin secretion through activity at the GIP receptor (GIPR) or the GLP-1R.Retatrutide is a synthetic peptide with glucose-lowering effects. It is an antidiabetic agent against type 2 diabetes (T2D), stimulating insulin and suppressing glucagon secretion in a glucose-dependent manner.Retatrutide was also shown to delay gastric emptying, lower fasting and postprandial glucose concentration, decrease food intake and reduce body weight in patients with type 2 diabetes.
Retatrutide (LY-3437943) was discovered by the American pharmaceutical company Eli Lilly and Company. It is a triple glucagon hormone receptor agonist (GLP-1, GIP, and GCGR receptors) for obesity. The 2024 Lasker~DeBakey Clinical Medical Research Award has been given to Joel Habener and Svetlana Mojsov for their discovery of a new hormone GLP-1(7-37) and to Lotte Knudsen for her role in developing sustained acting versions of this hormone as a treatment for obesity.

Basic Info

Product Name:

Retatrutide

Other Name:

Retatrutide;GIPR/GLP-1R;LY3437943Retatrutide;Retalutide;Retatrutide (sodium salt);Retatrutide RT5;retatrutide 5mg;Retatratide

CAS No.:

2381089-83-2

InChIKeys:

MLOLQJNKXBNWFW-SAGGEDDASA-N

Molecular Weight:

EC Number:

200-001-8

Color/Form:

White lyophilized

Categories:

Inhibitor Drugs

Characteristics

Water Solubility:

Soluble in water (5mg/ml).

Storage Conditions:

-20°C

Critical Temperature & Pressure:

-20°C

Research

Class:

Triple agonist — GCGR, GIPR, GLP-1R

Status:

Investigational (Phase 3)

Mechanism:

Simultaneously activates glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Engineered from the native GIP backbone with amino acid substitutions to confer GCGR and GLP-1R activity.

EC50 (Human GCGR):

5.79 nM

EC50 (Mouse GIPR):

0.191 nM

EC50 (Mouse GLP1R):

0.794 nM

EC50 (Mouse GCGR):

2.32 nM

EC50 (Human GLP1R):

0.775 nM

EC50 (Human GIPR):

0.0643 nM

Source:

Jastreboff AM, et al. N Engl J Med. 2023;389(6):514-526.DOI

Clinical Development:

NCT04881760; NCT05882045; NCT06354660

References

ChEMBL:

DrugBank:

KEGG DRUG:

PubChem:

Literature:

NEJM: Jastreboff et al. (2023) — Phase 2 Trial; FDA Drugs@FDA

Disclaimer:

Retatrutide is an investigational compound not yet approved by FDA or EMA. This listing is for industrial and laboratory research use only. Product information on ECHEMI is provided for sourcing and specification reference. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.

See More Retatrutide Properties 

Seller Information

Business Type:
Trader

Main Products:
pharmaceutical intermediates,peptides,electronic chemicals

Location:
Room 102, 1st Floor, East Office Building, No. 45 Pengwan Road, Qianwan Bonded Port Area, Qingdao Zone, China (Shandong) Pilot Free Trade Zone

Payment Terms:
100% TT in advance

Average lead Time:
10 days

Total Annual Revenue:
$10 million-$25 million

Total Employees:
51-100

Year of Establishment:
2024

A reliable supplier is like insurance.

We are mainly specilized in supply of pharmaceutical intermediates, electronic chemicals，food additives, and other fine chemical products.
Integrity is the foundation, quality is life. We would like to work together with you to build a greener and brighter future.

Website: orientchem.cc
Email: scarlett@orientchem.cc
WhatsApp: +86 17753254221

Inquiry History

7488 Inquiries

Country	Product	Purchase Quantity	Date Posted
United States	Retatrutide	60 G	Oct 28, 2026
Croatia	Retatrutide	10 MG	Oct 28, 2026
United States	Retatrutide	200 MG	Oct 28, 2026
Sweden	Retatrutide	10 MG	Oct 28, 2026
United States	Retatrutide	1 G	Oct 27, 2026
United Kingdom	Retatrutide	10 MG	Oct 27, 2026
Lithuania	Retatrutide	30 MG	Oct 27, 2026
United States	Retatrutide	10 MG	Oct 27, 2026
Greece	Retatrutide	30 MG	Oct 27, 2026
Germany	Retatrutide	20 MG	Oct 27, 2026
Canada	Retatrutide	30 MG	Oct 27, 2026
United States	retatrutide	40 MG	Oct 27, 2026
Spain	Retatrutide	30 MG	Oct 27, 2026
United Kingdom	Retatrutide	20 MG	Oct 27, 2026
United States	Retatrutide	40 MG	Oct 27, 2026
United States	Retatrutide	50 MG	Oct 27, 2026
United States	retatrutide	30 MG	Oct 27, 2026
United States	retatrutide	200 MG	Oct 27, 2026
Spain	retatrutide	200 MG	Oct 27, 2026
United States	Retatrutide	100 PCS	Oct 27, 2026

Go to Page

Post an enquiry for this product

More Choices Find All Products for Sale 

Product Name	Grade / Content	Price	Supplier Name	Details
99%+ high purity Retatrutide CAS 2381089-83-2 peptides Lyophilized Powder vilas for research Use	Pharmaceutical Grade/99	$1/UNIT FOB	Hangzhou Zhongma Trading Co., Ltd.	Inquiry
KLOW \| GLOW \| Peptide \| GHK-CU \| 99%Purity \| wholesale factory rate	Research Grade/99	$2-2.5/UNIT FOB	Huaian Camelot Cosmetics Co., Ltd.	Inquiry
Retatrutide CAS 2381089-83-2 99% Hot Sale Pharmaceutical Best Service Pharmaceutical Producer RT20 RT50 RT60	Pharmaceutical Grade/99	$33/MT FOB	Yiwu Xichai Biotechnology Co., Ltd.	Inquiry
Peptide RT rt10 Retatrutide TB500 Tirzepatide Semaglutide MOTS-C muscle gain body shaping support anabolic support fat metabolism	Pharmaceutical Grade/99.9	$30-36/UNIT FOB	Guangzhou Youfuyan Technology Co., Ltd.	Inquiry
High purity retatrutide 99% White powder High Quality peptide weight loss	Pharmaceutical Grade/99.99	$10/UNIT FOB	Jinan Pingxing Trading Co., Ltd.	Inquiry

Retatrutide 2381089-83-2 API

Product Details

Seller Information

Inquiry History

More Choices Find All Products for Sale 

Related Searches

More from this Seller